Post hoc analysis of the phase 3 QUEST trial and TRAVERSE extension in patients aged ≥12 with moderate-to-severe type 2 asthma: dupilumab vs placebo reduced severe exacerbations and improved FEV1 regardless of early transient blood eosinophil rises, sustained to week 96.
Secondary analysis
Pavord et al. Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthma